Dr. Reddy's Laboratories Ltd (RDY): Price and Financial Metrics

Dr. Reddy's Laboratories Ltd (RDY): $56.92

0.61 (+1.08%)

POWR Rating

Component Grades














  • RDY scores best on the Stability dimension, with a Stability rank ahead of 96.46% of US stocks.
  • The strongest trend for RDY is in Stability, which has been heading up over the past 177 days.
  • RDY's current lowest rank is in the Momentum metric (where it is better than 7.21% of US stocks).

RDY Stock Summary

  • Price to trailing twelve month operating cash flow for RDY is currently 0.26, higher than just 2.03% of US stocks with positive operating cash flow.
  • With a year-over-year growth in debt of -41.95%, DR REDDYS LABORATORIES LTD's debt growth rate surpasses merely 6.7% of about US stocks.
  • The volatility of DR REDDYS LABORATORIES LTD's share price is greater than that of just 0.2% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to DR REDDYS LABORATORIES LTD are BC, ITRN, LOGI, SBFM, and FOXF.
  • RDY's SEC filings can be seen here. And to visit DR REDDYS LABORATORIES LTD's official web site, go to www.drreddys.com.

RDY Stock Price Chart Interactive Chart >

Price chart for RDY

RDY Price/Volume Stats

Current price $56.92 52-week high $58.28
Prev. close $56.31 52-week low $49.59
Day low $56.72 Volume 37,396
Day high $57.11 Avg. volume 190,587
50-day MA $54.22 Dividend yield 0.57%
200-day MA $53.79 Market Cap 9.48B

Dr. Reddy's Laboratories Ltd (RDY) Company Bio

Dr. Reddy's Laboratories operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company was founded in 1984 and is based in Hyderabad, India.

RDY Latest News Stream

Event/Time News Detail
Loading, please wait...

RDY Latest Social Stream

Loading social stream, please wait...

View Full RDY Social Stream

Latest RDY News From Around the Web

Below are the latest news stories about DR REDDYS LABORATORIES LTD that investors may wish to consider to help them evaluate RDY as an investment opportunity.

Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases

HOUSTON, March 20, 2023--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced a worldwide agreement with Dr. Reddy’s Laboratories Limited. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as "Dr. Reddy’s"), a global pharmaceutical company. Under this agreement, Coya will in-license th

Yahoo | March 20, 2023

Dr. Reddy's Seeks Gaining Foothold In Women's Health Via Mayne Pharma's U.S. Generic Prescription Deal

Dr. Reddy's Laboratories Ltd (NYSE: RDY) has agreed to acquire the U.S. generic prescription product portfolio of Australia-based Mayne Pharma Group Limited (OTC: MAYND) (OTC: MAYNF) (OTC: MYPHY). Under the terms of the agreement, Dr. Reddy's will acquire the portfolio for an upfront payment of approximately $90 million in cash, with contingent payments of up to $15 million. Consideration towards inventory and credits for certain accrued channel liabilities are to be determined on the closing da

Yahoo | February 27, 2023

Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma’s U.S. Generic Prescription Product Portfolio

HYDERABAD, India & BASEL, Switzerland & PRINCETON, N.J., February 27, 2023--Dr. Reddy's Laboratories announces agreement to acquire Mayne Pharma’s U.S. generic prescription product portfolio.

Yahoo | February 27, 2023

Dr. Reddy’s included in Bloomberg Gender-Equality Index for the 6th year in a row and S&P Global’s Sustainability Yearbook for the 3rd year

HYDERABAD, India, February 08, 2023--Dr. Reddy’s Laboratories Ltd announced major back-to-back recognitions in gender equality and sustainability.

Yahoo | February 8, 2023

The 3 Most Undervalued Stocks in India for Your February Buy List

These are a few of the top undervalued stocks in India, providing investors with exposure to strong growth outlooks in the coming years.

Faisal Humayun on InvestorPlace | January 31, 2023

Read More 'RDY' Stories Here

RDY Price Returns

1-mo 6.99%
3-mo 9.99%
6-mo 8.75%
1-year 3.38%
3-year 44.80%
5-year 81.32%
YTD 9.99%
2022 -19.92%
2021 -7.49%
2020 76.61%
2019 8.38%
2018 1.18%

RDY Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full RDY Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8407 seconds.